Park Place Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Park Place Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$301K	Buy	675 +50	+8%	+$23.3K	0.06%	152
2025 Q4	$283K	Buy	625 +70	+13%	+$30.2K	0.06%	156
2025 Q3	$217K	Buy	555 +279	+101%	+$117K	0.05%	184
2025 Q2	$125K	Hold	276	–	–	0.03%	248
2025 Q1	$134K	Sell	276 -89	-24%	-$41.5K	0.04%	222
2024 Q4	$147K	Buy	365 +36	+11%	+$16.7K	0.04%	234
2024 Q3	$153K	Sell	329 -41	-11%	-$19.7K	0.04%	237
2024 Q2	$173K	Sell	370 -422	-53%	-$183K	0.06%	227
2024 Q1	$331K	Sell	792 -507	-39%	-$214K	0.12%	170
2023 Q4	$529K	Buy	1,299 +286	+28%	+$106K	0.21%	131
2023 Q3	$352K	Sell	1,013 -207	-17%	-$72.4K	0.1%	177
2023 Q2	$429K	Sell	1,220 -213	-15%	-$71.8K	0.12%	158
2023 Q1	$451K	Sell	1,433 -666	-32%	-$200K	0.13%	156
2022 Q4	$606K	Buy	+2,099	New	+$640K	0.17%	134

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Park Place Capital's VRTX Position: Q1 2026 in Review

Park Place Capital increased its Vertex Pharmaceuticals (VRTX) stake by 8% in Q1 2026, buying an estimated $23.3K and bringing the position to 675 shares worth $301K. The position accounts for 0.06% of the portfolio, ranked #152.

Park Place Capital first reported a position in VRTX in Q4 2022 and has held it in 14 quarters since. The position peaked at $606K in Q4 2022. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Park Place Capital held 675 shares of Vertex Pharmaceuticals worth $301K as of Q1 2026.
Park Place Capital bought 50 Vertex Pharmaceuticals shares in Q1 2026, an estimated $23.3K.
Vertex Pharmaceuticals made up 0.06% of Park Place Capital's portfolio in Q1 2026, its #152 holding.
Park Place Capital first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
Park Place Capital's Vertex Pharmaceuticals position peaked at $606K in Q4 2022.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Park Place Capital's 13F filing for Q1 2026, filed 9 Apr 2026.